+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Head & Neck Cancer Drugs Market by Drug Class (Chemotherapy Agents, Immunotherapy, Monoclonal Antibodies), Route Of Administration (Intravenous, Oral, Subcutaneous), Cancer Type, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Head & Neck Cancer Drugs Market by Drug Class (Chemotherapy Agents, Immunotherapy, Monoclonal Antibodies), Route Of Administration (Intravenous, Oral, Subcutaneous), Cancer Type, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Sale

Head & Neck Cancer Drugs Market by Drug Class (Chemotherapy Agents, Immunotherapy, Monoclonal Antibodies), Route Of Administration (Intravenous, Oral, Subcutaneous), Cancer Type, Distribution Channel, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 192 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5454865
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The head and neck cancer drugs market is undergoing dynamic evolution as major innovations in therapeutics continue to influence clinical practice and reshape the pharmaceutical landscape for oncology leaders and stakeholders.

Market Snapshot: Head & Neck Cancer Drugs Market

The Head & Neck Cancer Drugs Market grew from USD 1.56 billion in 2024 to USD 1.81 billion in 2025. It is expected to continue growing at a CAGR of 15.47%, reaching USD 3.70 billion by 2030.

Scope & Segmentation

This report provides a comprehensive analysis of the head and neck cancer drugs ecosystem by breaking down the market into multiple actionable segments and highlighting geographic, therapeutic, and operational insights relevant to industry decision-makers.

  • Drug Classes: Chemotherapy agents, immunotherapy, monoclonal antibodies, and tyrosine kinase inhibitors are central to current and emerging treatment protocols.
  • Route of Administration: Key administration routes include intravenous infusion, oral medications, and subcutaneous injection—each shaping patient experience and compliance.
  • Cancer Types: Covered categories comprise nasopharyngeal carcinoma, salivary gland tumors, sinonasal tumors, squamous cell carcinoma, and thyroid cancer, emphasizing the need for tailored clinical strategies.
  • Distribution Channels: The network spans hospital pharmacy (including inpatient and outpatient settings) and retail pharmacy (such as chain and independent providers), impacting drug availability and market reach.
  • End Users: Hospitals (private and public), cancer clinics, ambulatory surgical centers, home care settings, multispecialty clinics, and specialty clinics reflect the diversity of care environments.
  • Regions: The study includes detailed market analysis for the Americas, Europe, Middle East & Africa, and Asia-Pacific, with country- and state-level granularity in the United States, major European nations, and leading Asia-Pacific markets.
  • Leading Companies: Industry participants analyzed in depth include Merck & Co., Bristol-Myers Squibb, Eli Lilly, Roche, AstraZeneca, Pfizer, Johnson & Johnson, Novartis, GlaxoSmithKline, and Amgen.

Key Takeaways for Senior Decision-Makers

  • Therapeutic innovation is advancing personalized care through targeted and immune-based treatments, influencing strategic portfolio priorities.
  • Regulatory and payer environments are in flux, prompting the integration of real-world evidence and value-based frameworks into commercial strategies.
  • Market access is shaped by the interplay of new modalities, evolving distribution channels, and shifting clinical practice patterns.
  • Regional opportunities are expanding as emerging markets prioritize oncology infrastructure and local partnerships, while established regions drive research and rapid adoption.
  • Collaborative strategies with contract manufacturing, digital health platforms, and supply chain diversification are increasingly critical for resilience and scalability.
  • Tailored segmentation by drug class, administration route, and patient setting is enabling precise alignment with clinical demand and formulary pathways.

Tariff Impact: Addressing Trade and Cost Pressures

Recent tariff adjustments in the United States have heightened cost pressures on pharmaceutical manufacturers importing active ingredients, influencing both production expenses and price negotiations. These developments drive investments in procurement strategy adaptation, domestic capacity, and collaboration to offset the financial impact across the head and neck cancer pipeline. Strategic flexibility and careful supply chain management are becoming requirements in this environment.

Primary Keyword: Head & Neck Cancer Drugs Market

Methodology & Data Sources

Analysis is grounded in multi-tiered research: peer-reviewed literature, clinical trial registries, and regulatory filings form the secondary base, while in-depth interviews with industry leaders and clinical stakeholders inform key trends and pipeline insights. Data validation, segmentation by cancer type and drug class, and regional analysis were rigorously applied. An expert review process ensures reliability for strategic decision-making.

Why This Report Matters

  • Offers senior executives a concise, actionable overview supporting confident strategic investment, product development, and partnership decisions in the oncology sector.
  • Equips teams with market structure clarity, segmentation depth, and regional intelligence to target growth, optimize commercialization, and ensure competitive positioning in the evolving landscape.

Conclusion

This report provides leaders with a clear understanding of the current landscape and actionable guidance to navigate future shifts in the head and neck cancer drugs market. The insights help inform critical business and clinical decisions for sustainable growth and innovation.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of PD-1/PD-L1 inhibitor combination therapies in first-line treatment for recurrent and metastatic head and neck cancer
5.2. Advancements in HPV targeted vaccine candidate pipelines aiming to prevent oropharyngeal cancers in high-risk populations
5.3. Emergence of novel antibody-drug conjugates targeting EGFR for improved head and neck tumor selectivity
5.4. Implementation of liquid biopsy monitoring to guide personalized therapy decisions in head and neck carcinoma
5.5. Evaluation of neoadjuvant immunotherapy regimens to increase surgical resectability in locally advanced head and neck cancer
5.6. Development of bispecific T cell engager molecules for enhanced antitumor activity in head and neck squamous cell carcinoma
5.7. Incorporation of real-world evidence and patient-reported outcomes in regulatory submissions for head and neck oncology drugs
5.8. Optimization of radiotherapy and checkpoint inhibitor dosing schedules to maximize efficacy and minimize toxicity in head and neck tumors
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Head & Neck Cancer Drugs Market, by Drug Class
8.1. Introduction
8.2. Chemotherapy Agents
8.2.1. Fluoropyrimidines
8.2.2. Platinum Compounds
8.2.3. Taxanes
8.3. Immunotherapy
8.3.1. PD-1 Inhibitors
8.3.2. PD-L1 Inhibitors
8.4. Monoclonal Antibodies
8.4.1. EGFR Inhibitors
8.5. Tyrosine Kinase Inhibitors
8.5.1. EGFR TKIs
8.5.2. VEGFR TKIs
9. Head & Neck Cancer Drugs Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous
10. Head & Neck Cancer Drugs Market, by Cancer Type
10.1. Introduction
10.2. Nasopharyngeal Carcinoma (NPC)
10.3. Salivary Gland Tumors
10.4. Sinonasal Tumors
10.5. Squamous Cell Carcinoma (HNSCC)
10.6. Thyroid Cancer
11. Head & Neck Cancer Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.2.1. Inpatient Pharmacy
11.2.2. Outpatient Pharmacy
11.3. Retail Pharmacy
11.3.1. Chain Pharmacy
11.3.2. Independent Pharmacy
12. Head & Neck Cancer Drugs Market, by End User
12.1. Introduction
12.2. Ambulatory Surgical Centers
12.3. Cancer Clinics
12.3.1. Multispecialty Clinics
12.3.2. Specialty Clinics
12.4. Home Care Settings
12.5. Hospitals
12.5.1. Private Hospitals
12.5.2. Public Hospitals
13. Americas Head & Neck Cancer Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Head & Neck Cancer Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Head & Neck Cancer Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Merck & Co., Inc.
16.3.2. Bristol-Myers Squibb Company
16.3.3. Eli Lilly and Company
16.3.4. Roche Holding AG
16.3.5. AstraZeneca PLC
16.3.6. Pfizer Inc.
16.3.7. Johnson & Johnson
16.3.8. Novartis AG
16.3.9. GlaxoSmithKline plc
16.3.10. Amgen Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. HEAD & NECK CANCER DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. HEAD & NECK CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. HEAD & NECK CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. HEAD & NECK CANCER DRUGS MARKET: RESEARCHAI
FIGURE 26. HEAD & NECK CANCER DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 27. HEAD & NECK CANCER DRUGS MARKET: RESEARCHCONTACTS
FIGURE 28. HEAD & NECK CANCER DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. HEAD & NECK CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY FLUOROPYRIMIDINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY FLUOROPYRIMIDINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY TAXANES, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY TAXANES, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY EGFR TKIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY EGFR TKIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY VEGFR TKIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY VEGFR TKIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY NASOPHARYNGEAL CARCINOMA (NPC), BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY NASOPHARYNGEAL CARCINOMA (NPC), BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY SALIVARY GLAND TUMORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY SALIVARY GLAND TUMORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY SINONASAL TUMORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY SINONASAL TUMORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY SQUAMOUS CELL CARCINOMA (HNSCC), BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY SQUAMOUS CELL CARCINOMA (HNSCC), BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY THYROID CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY THYROID CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY INPATIENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY INPATIENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY OUTPATIENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY OUTPATIENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY MULTISPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY MULTISPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER CLINICS, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER CLINICS, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER CLINICS, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER CLINICS, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER CLINICS, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER CLINICS, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 159. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 160. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 161. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 162. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 163. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 164. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 165. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 166. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 167. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 168. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 169. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 170. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 171. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 172. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 173. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 174. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 175. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 176. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 177. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 178. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 179. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 180. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 181. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER CLINICS, 2018-2024 (USD MILLION)
TABLE 182. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER CLINICS, 2025-2030 (USD MILLION)
TABLE 183. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 184. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 185. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 186. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 187. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 188. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 189. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 190. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 191. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 192. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 193. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 194. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 195. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 196. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 197. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 198. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 199. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 200. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 201. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 202. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 203. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 204. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 205. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER CLINICS, 2018-2024 (USD MILLION)
TABLE 208. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER CLINICS, 2025-2030 (USD MILLION)
TABLE 209. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 210. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 219. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 220. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 221. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 222. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 223. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 224. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 225. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 226. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 227. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 228. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 229. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 230. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 231. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER CLINICS, 2018-2024 (USD MILLION)
TABLE 234. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER CLINICS, 2025-2030 (USD MILLION)
TABLE 235. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 236. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 239. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 240. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 241. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 242. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 243. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 244. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 245. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 246. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 247. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 248. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 249. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 250. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 251. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 252. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 253. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 254. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 255. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 256. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 257. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 258. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 259. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER CLINICS, 2018-2024 (USD MILLION)
TABLE 260. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER CLINICS, 2025-2030 (USD MILLION)
TABLE 261. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 262. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 281. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER CLINICS, 2018-2024 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER CLINICS, 2025-2030 (USD MILLION)
TABLE 287. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 290. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 291. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 292. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 293. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 294. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 295. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 296. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 297. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 298. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 299. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 300. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 301. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 302. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 303. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 304. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 305. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 306. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 307. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 308. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 309. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (

Samples

Loading
LOADING...

Companies Mentioned

  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Roche Holding AG
  • AstraZeneca PLC
  • Pfizer Inc.
  • Johnson & Johnson
  • Novartis AG
  • GlaxoSmithKline plc
  • Amgen Inc.

Table Information

Report AttributeDetails
No. of Pages192
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.81 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.7 Billion
Compound Annual Growth Rate15.4%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Head and Neck Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Head and Neck Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Head and Neck Cancer Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034) - Product Image

Head and Neck Cancer Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)

  • Report
  • 400 Pages
  • Global
From
Head and Neck Cancer Therapeutics - Global Strategic Business Report - Product Image

Head and Neck Cancer Therapeutics - Global Strategic Business Report

  • Report
  • 183 Pages
  • Global
From
Head And Neck Cancer Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033 - Product Image

Head And Neck Cancer Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033

  • Report
  • 105 Pages
  • Global
From
PD-1 Resistant Head and Neck Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

PD-1 Resistant Head and Neck Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From

About the Head and Neck Cancer Drug Market

The Head and Neck Cancer Drug market is a subset of the larger Oncology Drugs market. It includes drugs used to treat cancers of the head and neck, such as squamous cell carcinoma, salivary gland cancer, and nasopharyngeal cancer. These drugs are typically used in combination with radiation therapy and/or surgery to treat the cancer. Common drugs used in this market include chemotherapy, targeted therapy, immunotherapy, and monoclonal antibodies. The Head and Neck Cancer Drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in this market include Bristol-Myers Squibb, Merck & Co., Pfizer, AstraZeneca, and Roche. Other companies include Novartis, Eli Lilly, and GlaxoSmithKline. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.